- Home
- GHRS vs CDNA Comparison
GHRS vs CDNA Comparison
Compare GHRS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | CDNA |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GHRS | CDNA |
|---|---|---|
| Price | $15.15 | $19.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $32.90 | $26.67 |
| AVG Volume (30 Days) | 248.6K | ★ 679.3K |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.49 |
| Revenue Next Year | N/A | $11.32 |
| P/E Ratio | ★ N/A | $16.93 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $7.98 | $10.96 |
| 52 Week High | $19.51 | $25.55 |
Technical Indicators
Market Signals| Indicator | GHRS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 48.86 |
| Support Level | $13.60 | $18.24 |
| Resistance Level | $15.88 | $21.40 |
| Average True Range (ATR) | 0.94 | 1.08 |
| MACD | -0.20 | -0.11 |
| Stochastic Oscillator | 42.46 | 44.62 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.